My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: probably not. Compounded GLP‑1s are usually a last-resort option because of quality, safety, and legal/coverage issues. You likely have safer and more practical alternatives — appeals, manufacturer help, other FDA‑approved drugs, or clinic self-pay programs — that are worth trying first.

What I would do next (practical steps)

1. Appeal the denial

• Ask your prescriber to submit or re-submit a prior‑authorization with a letter of medical necessity stating your BMI, weight‑related comorbidities, prior weight‑loss attempts, and why Wegovy is clinically indicated.
• Request a peer‑to‑peer review between your prescriber and the insurer’s medical reviewer.
• File the insurer’s internal and (if necessary) external/independent review appeals. I can help draft a short appeal letter if you want.

1. Check manufacturer assistance and coupons

• Novo Nordisk (Wegovy) offers patient support programs and savings/coupon programs for eligible commercially insured patients; they also have a patient assistance program for eligible uninsured/low‑income patients. Contact Novo Nordisk or your prescriber’s office for enrollment help.
• If you’re able to try an alternative, Eli Lilly has programs for tirzepatide (Zepbound for obesity; Mounjaro for diabetes) with savings and assistance options.

1. Ask about alternative FDA‑approved options

• Saxenda (liraglutide) — an FDA‑approved GLP‑1 for weight management; may be covered differently than Wegovy.
• Zepbound (tirzepatide) — approved for weight management (if available where you live).
• Mounjaro (tirzepatide) and Ozempic (semaglutide) are approved for diabetes and sometimes used off‑label for weight; coverage varies.
• Non‑GLP‑1 antiobesity drugs: Qsymia (phentermine/topiramate), Contrave (bupropion/naltrexone), Xenical/Alli (orlistat) — these may be cheaper or easier to get coverage for in some plans.

1. Consider low‑cost clinics or self‑pay weight‑management programs

• Many weight‑management clinics offer GLP‑1 treatment programs at a self‑pay rate; some patients find this less expensive than paying out of pocket to a compounding pharmacy. Ask about total monthly price, lab monitoring, and provider follow‑up.

Why compounded GLP‑1s are usually not the best first choice

• Compounded drugs are not FDA‑approved: compounding pharmacies may vary in potency, sterility, and labeling accuracy. There have been reports of incorrect doses and contamination with compounded injectables.
• Legal and insurance problems: insurers typically won’t cover compounded versions of brand drugs, and using compounding to skirt coverage could be risky.
• Safety: injectable compounding requires strict sterile technique; improperly compounded injectable medications have led to severe infections in the past.
• Lack of trial data: efficacy and side‑effect profiles of compounded formulations and nonstandard dosing aren’t backed by the large trials that support brand products.

If you still consider a compounded GLP‑1

• Only use a compounding pharmacy with strong credentials: state licensure, accreditation (PCAB or other), and evidence they follow USP sterility standards (USP <797>/<800>). Ask for a certificate of analysis, sterility testing, and lot traceability.
• Discuss with your prescriber the exact formulation and dosing, and make sure you’ll get appropriate follow‑up (labs, GI monitoring, cardiac history where relevant).
• Know the legal/insurance implications and get written informed consent covering risks and why you chose this path.

Other things I can help with

• Drafting an appeal/medical‑necessity letter for your provider to send.
• Comparing likely costs for brand drugs (Wegovy, Zepbound, Saxenda, Mounjaro) vs clinic self‑pay vs compounding in your area (if you tell me your zip code and insurance type).
• Finding manufacturer assistance or patient‑support contact details.

If you want, tell me: what type of insurance do you have (commercial, Medicaid, Medicare/Part D, none), why the denial said (medical necessity, formulary, step therapy), and whether your prescriber already tried alternatives — I’ll give more specific next steps.